RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Jahanban Esfahlan, Rana ^a   Seidi, Khaled ^a   Monhemi, Hassan ^b   Adli, Amir Daei Farshchi ^a   Minofar, Babak ^g,h   Zare, Peyman ^c   Farajzadeh, Davoud ^d   Farajnia, Safar ^e   Behzadi, Ramezan ^f   Abbasi, Mehran Mesgari ^d   Zarghami, Nosratollah ^a,j   Javaheri, Tahereh ⁱ  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Structural Biology and Bioinformatics Research Group   (Iran)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d AZARBAIJAN SHAHID MADANI UNIVERSITY   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f PASTEUR INSTITUTE OF IRAN   (Iran)

^g UNIVERSITY OF SOUTH BOHEMIA   (Czech Republic)

^h INSTITUTE OF MICROBIOLOGY   (Czech Republic)

ⁱ UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^j TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYL-GLYCYL-ASPARTIC ACID; BACTERIAL PROTEIN; COAGULASE; FUSION PROTEIN; OLIGOPEPTIDE;

ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG SCREENING; GENETICS; HUMAN; INFARCTION; METABOLISM; MUTATION; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PROCEDURES; THROMBOSIS; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; BACTERIAL PROTEINS; CELL LINE, TUMOR; CELLS, CULTURED; COAGULASE; HUMANS; INFARCTION; MICE, INBRED C57BL; MICE, NUDE; MUTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; RECOMBINANT FUSION PROTEINS; THROMBOSIS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85027521856     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-05326-9     Document Type: Article

References (47)

1. Jahanban-Esfahlan, R., de la Guardia, M., Ahmadi, D., Yousefi, B. Modulating tumor hypoxia by nanomedicine for effective cancer therapy. J. Cell. Physiol, doi: 10.1002/jcp.25859 (2017).
2. Liu, C., et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer. Res 62, 5470-5475 (2002).
3. Bieker, R., et al. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: Experimental results and first-in-man experience. Blood 113, 5019-5027, doi: 10.1182/blood-2008-04-150318 (2009).
4. Hu, P., et al. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer. Res 63, 5046-5053 (2003).
5. Huang, F. Y., et al. A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model. J. Zhejiang. Univ. Sci. B 9, 602-609 (2008).
6. Huang, X., et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275, 547-550 (1997).
7. Kessler, T., et al. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin. Cancer. Res 11, 6317-6324, doi: 10.1158/1078-0432.ccr-05-0389 (2005).
8. Nilsson, F., Kosmehl, H., Zardi, L., Neri, D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer. Res 61, 711-716 (2001).
9. Ran, S., et al. Infarction of solid hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer. Res 58, 4646-4653 (1998).
10. Brand, C., et al. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor. Oncotarget 7, 6774-6789, doi: 10.18632/oncotarget.6725 (2016).
11. Liu, S. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: Maximizing binding affinity via bivalency. Bioconjug. Chem 20, 2199-2213, doi: 10.1021/bc900167c (2009).
12. Camerer, E., Huang, W., Coughlin, S. R. Tissue factor-and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc. Natl. Acad. Sci. USA 97, 5255-5260 (2000).
13. Seidi, K., Jahanban-Esfahlan, R., Zarghami, N. Tumor rim cells: From resistance to vascular targeting agents (VTAs) to complete tumor ablation. Tumor. Biol 39, 1-15, doi: 10.1177/1010428317691001 (2017).
14. Jahanban-Esfahlan, R., Seidi, K., Zarghami, N. Tumor vascular infarction: Prospects and challenges. Int. J. Hematol 105, 244-256, doi: 10.1007/s12185-016-2171-3 (2017).
15. Friedrich, R., et al. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 425, 535-539, doi: 10.1038/nature01962 (2003).
16. Friedrich, R., et al. Structural basis for reduced staphylocoagulase-mediated bovine prothrombin activation. J. Biol. Chem 281, 1188-1195, doi: 10.1074/jbc.M507957200 (2006).
17. Panizzi, P., Friedrich, R., Fuentes-Prior, P., Bode, W., Bock, P. E. The staphylocoagulase family of zymogen activator and adhesion proteins. Cell. Mol. Life. Sci 61, 2793-2798, doi: 10.1007/s00018-004-4285-7 (2004).
18. Panizzi, P., et al. Fibrinogen substrate recognition by staphylocoagulase.(pro)thrombin complexes. J. Biol. Chem 281, 1179-1187, doi: 10.1074/jbc.M507956200 (2006).
19. Yokota, N., et al. Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice. J. Thromb. Haemost 12, 71-81, doi: 10.1111/jth.12442 (2014).
20. Nierodzik, M. L., Karpatkin, S. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer. Cell 10, 355-362, doi: 10.1016/j.ccr.2006.10.002 (2006).
21. Cheng, A. G., et al. Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS. Pathog 6, e1001036, doi: 10.1371/journal.ppat.1001036 (2010).
22. Bode, W., Huber, R. Induction of the bovine trypsinogen-trypsin transition by peptides sequentially similar to the N-terminus of trypsin. FEBS Lett 68, 231-236, doi: 10.1016/0014-5793(76)80443-7 (1976).
23. Xiong, J. P., et al. Crystal structure of the extracellular segment of integrin alpha V beta 3 in complex with an Arg-Gly-Asp ligand. Science 296, 151-155, doi: 10.1126/science.1069040 (2002).
24. Pencik, J., et al. STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun 6, 7736, doi: 10.1038/ncomms8736 (2015).
25. Huang, Z. J., et al. Targeting the vasculature of colorectal carcinoma with a fused protein of (RGD)(3)-tTF. Sci. World. J 2013, 637086, doi: 10.1155/2013/637086 (2013).
26. Mojovic, B., Mojovic, N., Tager, M., Drummond, M. C. Staphylocoagulase as a hemostatic agent. Yale. J. Biol. Med 42, 11-20 (1969).
27. Jeljaszewicz, J., Niewiarowski, S., Poplawski, A., Prokopowicz, J., Worowski, K. Intravascular coagulation and fibrinolysis by Staphylocoagulase. Comparision with thrombin. Thrombosis. Et. Diathesis. Haemorrhagica 13, 457-469 (1965).
28. Soulier, J. P., et Prou-Wartelle, O. Effets de l'injection de staphylocoagulase chez le lapin. Essais de prevention du syndrome de defibrination. Nouvelle. Revue. Franc. d'Hematologie 7, 779-800 (1967).
29. Ruf, W., Mueller, B. M. Thrombin generation and the pathogenesis of cancer. Semin. Thromb. Hemost 32(Suppl 1), 61-68, doi: 10.1055/s-2006-939555 (2006).
30. Zigler, M., Kamiya, T., Brantley, E. C., Villares, G. J., Bar-Eli, M. PAR-1 and thrombin: The ties that bind the microenvironment to melanoma metastasis. Cancer. Res 71, 6561-6566, doi: 10.1158/0008-5472.can-11-1432 (2011).
31. Jiang, X., et al. Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells. J. Thromb. Haemost 2, 93-101 (2004).
32. Lima, L. G., Monteiro, R. Q. Activation of blood coagulation in cancer: Implications for tumour progression. Biosci. Rep 33, e00064, doi: 10.1042/BSR20130057 (2013).
33. Reid, H. A., Chan, K. E. The paradox in therapeutic defibrination. Lancet 1, 485-486 (1968).
34. Yang, J., et al. The I-TASSER Suite: Protein structure and function prediction. Nat. Meth 12, 7-8, doi: 10.1038/nmeth.3213 (2015).
35. van Zundert, G. C., et al. The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes. J. Mol. Biol 428, 720-725, doi: 10.1016/j.jmb.2015.09.014 (2016).
36. Lindahl, E., Hess, B., van der Spoel, D. A message-passing parallel molecular dynamics implementation. Comput. Phys. Commun 91, 43-56 (1995).
37. Schmid, N., et al. Definition and testing of the GROMOS force-field versions 54A7 and 54B7. Eur. Biophys. J 40, 843-856, doi: 10.1007/s00249-011-0700-9 (2011).
38. Hermans, J., Berendsen, H. J. C., Van Gunsteren, W. F., Postma, J. P. M. A consistent empirical potential for water-protein interactions. Biopolymers 23, 1513-1518, doi: 10.1002/bip.360230807 (1984).
39. Hess, B., Bekker, H., Berendsen, H. J. C., Fraaije, J. G. E. M. LINCS: A linear constraint solver for molecular simulations. J. Comput. Chem 18, 1463-1472, doi:10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H (1997).
40. Miyamoto, S., Kollman, P. A. Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models. J. Comput. Chem 13, 952-962, doi: 10.1002/jcc.540130805 (1992).
41. Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A., Haak, J. R. Molecular dynamics with coupling to an external bath. J. Chem. Phys 81, 3684-3690 (1984).
42. Darden, T., York, D., Pedersen, L. Particle mesh Ewald: An Nlog(N):method for Ewald sums in large systems. J. Chem. Phys 98, 10089-10092 (1993).
43. Delano, W. The PyMOL Molecular Graphics System. Available from: Citeulike-article-id:2816763. http://www.pymol.org (2002).
44. McAdow, M., et al. Coagulases as determinants of protective immune responses against Staphylococcus aureus. Infect. Immun 80, 3389-3398, doi: 10.1128/iai.00562-12 (2012).
45. Kazemi, Z., et al. Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation. Mol. Pharmacol 89, 630-644, doi: 10.1124/mol.116.103267 (2016).
46. Minas, T. Z., et al. YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model. Oncotarget 6, 37678-37694, doi: 10.18632/oncotarget.5520 (2015).
47. Javaheri, T., et al. Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation. Cell death Dis 7, e2419, doi: 10.1038/cddis.2016.268 (2016).